Back to Treatments

Treatment

Pemigatinib (FGFR2 Inhibitor)

1
Conditions
30
Trials
500
Participants
40%
Average Safety

Condition Evidence

Gallbladder and biliary tract cancer

30 trials · 500 participants

50% effectiveness · 40% safety
Pemigatinib (FGFR2 Inhibitor) | DFDA